$131 Million is the total value of Ponoi II Management, LLC's 5 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
NGM | NGM Biopharmaceuticals Inc | $37,759,000 | -4.1% | 1,298,908 | 0.0% | 28.92% | +0.8% | |
CNST | Constellation Pharmaceuticals Inc. | $36,821,000 | -18.8% | 1,574,229 | 0.0% | 28.20% | -14.6% | |
RVMD | Revolution Medicines Inc | $31,428,000 | +15.9% | 685,011 | 0.0% | 24.07% | +21.8% | |
NRIX | Nurix Therapeutics Inc | $21,336,000 | -5.4% | 686,274 | 0.0% | 16.34% | -0.6% | |
RAPT | RAPT Therapeutics Inc | $3,228,000 | +12.4% | 145,401 | 0.0% | 2.47% | +18.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
NGM Biopharmaceuticals Inc | 8 | Q3 2022 | 45.2% |
Revolution Medicines Inc | 8 | Q3 2022 | 38.8% |
Nurix Therapeutics Inc | 8 | Q3 2022 | 24.9% |
RAPT Therapeutics Inc | 8 | Q3 2022 | 9.7% |
Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 43.1% |
View Ponoi II Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-04-08 |
4 | 2023-11-17 |
4 | 2023-02-01 |
4 | 2023-01-25 |
4 | 2023-01-23 |
4 | 2023-01-17 |
4 | 2023-01-12 |
4 | 2022-12-14 |
4 | 2022-11-23 |
13F-HR | 2022-11-14 |
View Ponoi II Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.